Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma

NCT06414434 is registered in ClinicalTrials.gov with Michael Wagner, MD as lead sponsor.

NCT NCT06414434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06414434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma
Lead sponsor
Michael Wagner, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 30, 2024
Completion date
June 1, 2027
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cic-rearranged sarcoma, liposarcoma, mdm2 gene amplification, metastatic liposarcoma, myxoid liposarcoma, recurrent liposarcoma, unresectable liposarcoma